Physician profile
Amy Lobrano
NPI 1255382909
$3,455.61
in general payments reported to CMS, 2019-2025
30 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.38 · 2020: $111 · 2021: $243 · 2022: $176 · 2023: $743 · 2024: $1,416 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $42.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,786.51 |
| Education | $42.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.57 | 2019-2025 | |
| Janssen Biotech, INC. | $463.27 | 2019-2024 | Stelara, Simponi, Tremfya |
| Celgene Corporation | $191.15 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $160.33 | 2022-2024 | Cre Pro |
| Genzyme Corporation | $160.06 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $159.85 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.83 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $132.44 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $131.40 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Pfizer INC. | $131.17 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $107.81 | 2024-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $102.66 | 2020-2025 | Entyvio |
| Gilead Sciences, INC. | $95.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $71.07 | 2023 | Dupixent |
| Lilly USA, LLC | $52.81 | 2024 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $50.16 | 2025 | Rezdiffra |
| Celltrion USA INC. | $42.90 | 2024 | Zymfentra |
| Amgen INC. | $39.19 | 2025 | Uplizna |
| Allergan, INC. | $37.93 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.57 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $29.51 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $29.38 | 2023-2024 | Gimoti |
| Ferring Pharmaceuticals INC. | $21.57 | 2024 | Rebyota |
| Fresenius Kabi USA, LLC | $21.34 | 2024 | Idacio |
| Novo Nordisk INC | $20.05 | 2025 | Wegovy |
| Enterra Medical, INC. | $18.28 | 2024 | |
| Capsovision, INC. | $17.44 | 2025 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $14.99 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $13.49 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lobrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.